New AZ chief gets $6.4M to make up for Roche forfeit

AstraZeneca ($AZN) didn't send flowers to Pascal Soriot to woo him away from Roche ($RHHBY). No, its new chief executive got something much more valuable in the bargain: A £4 million ($ 6.44 million) payment. It's not exactly a signing bonus, though. The $6.44 million compensates Soriot for his loss of long-term incentive compensation from Roche. Story